CY1125266T1 - To rad1901 για χρηση στη θεραπεια του καρκινου των ωοθηκων - Google Patents

To rad1901 για χρηση στη θεραπεια του καρκινου των ωοθηκων

Info

Publication number
CY1125266T1
CY1125266T1 CY20211101023T CY211101023T CY1125266T1 CY 1125266 T1 CY1125266 T1 CY 1125266T1 CY 20211101023 T CY20211101023 T CY 20211101023T CY 211101023 T CY211101023 T CY 211101023T CY 1125266 T1 CY1125266 T1 CY 1125266T1
Authority
CY
Cyprus
Prior art keywords
ovarian cancer
rad1901
treatment
disclosed
methods
Prior art date
Application number
CY20211101023T
Other languages
English (en)
Inventor
Gary Hattersley
Original Assignee
Radius Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Radius Pharmaceuticals, Inc. filed Critical Radius Pharmaceuticals, Inc.
Publication of CY1125266T1 publication Critical patent/CY1125266T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Δημοσιοποιούνται μέθοδοι θεραπείας του καρκίνου των ωοθηκών.
CY20211101023T 2016-09-27 2021-11-24 To rad1901 για χρηση στη θεραπεια του καρκινου των ωοθηκων CY1125266T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662400495P 2016-09-27 2016-09-27
PCT/US2017/053834 WO2018064231A1 (en) 2016-09-27 2017-09-27 Methods for treating ovarian cancer

Publications (1)

Publication Number Publication Date
CY1125266T1 true CY1125266T1 (el) 2023-03-24

Family

ID=61760096

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211101023T CY1125266T1 (el) 2016-09-27 2021-11-24 To rad1901 για χρηση στη θεραπεια του καρκινου των ωοθηκων

Country Status (21)

Country Link
US (2) US20200009085A1 (el)
EP (1) EP3518911B1 (el)
JP (1) JP2019532934A (el)
KR (2) KR20230152814A (el)
CN (1) CN109715149A (el)
AU (1) AU2017336564A1 (el)
BR (1) BR112019004276A2 (el)
CA (1) CA3036568A1 (el)
CY (1) CY1125266T1 (el)
ES (1) ES2898072T3 (el)
HR (1) HRP20211804T1 (el)
HU (1) HUE057064T2 (el)
IL (1) IL265537B2 (el)
LT (1) LT3518911T (el)
MX (1) MX2019003311A (el)
PL (1) PL3518911T3 (el)
PT (1) PT3518911T (el)
RS (1) RS62660B1 (el)
SG (2) SG10202104282SA (el)
SI (1) SI3518911T1 (el)
WO (1) WO2018064231A1 (el)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020311337A1 (en) * 2019-07-07 2022-01-20 Olema Pharmaceuticals, Inc. Regimens of estrogen receptor antagonists

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
CN1927815A (zh) * 2006-09-25 2007-03-14 天津理工大学 邻苄胺基苯基醚化合物、化合物的衍生物及其制备方法与用途
MX2009013575A (es) * 2007-06-12 2010-07-02 Schering Corp Biomarcador de histona h2ax (hh2ax) para sensibilidad de inhibidores de farnesil proteina transferasa.
GB201217439D0 (en) * 2012-09-28 2012-11-14 Topotarget As Combination therapy
JP6389517B2 (ja) * 2013-06-19 2018-09-12 セラゴン ファーマシューティカルズ， インク． アゼチジンエストロゲン受容体調節因子及びその使用
CN104436194B (zh) * 2013-09-18 2018-03-30 北京大学 具有协同增效作用的抗癌组合物
CN106572990A (zh) * 2014-03-13 2017-04-19 豪夫迈·罗氏有限公司 含有雌激素受体调节剂的治疗性组合产品
US9421264B2 (en) * 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
MA53837A (fr) * 2014-12-18 2021-11-10 Hoffmann La Roche Tetrahydro-pyrido[3,4-b]indoles modulateurs des récepteurs des oestrogènes et leurs utilisations
CN105848374A (zh) * 2015-01-12 2016-08-10 芋头科技（杭州）有限公司 一种灯光控制系统及方法
EP4056127A1 (en) * 2015-01-28 2022-09-14 DePuy Synthes Products, Inc. Battery enclosure for sterilizeable surgical tools having thermal insulation
CN113750091A (zh) * 2015-04-29 2021-12-07 雷迪厄斯制药公司 用于治疗癌症的方法

Also Published As

Publication number Publication date
EP3518911A4 (en) 2020-05-13
MX2019003311A (es) 2019-07-08
IL265537B (en) 2022-12-01
CA3036568A1 (en) 2018-04-05
SI3518911T1 (sl) 2022-02-28
RU2019108382A3 (el) 2020-12-28
HRP20211804T1 (hr) 2022-02-18
PT3518911T (pt) 2021-11-11
US20200009085A1 (en) 2020-01-09
AU2017336564A1 (en) 2019-03-14
RU2019108382A (ru) 2020-10-29
PL3518911T3 (pl) 2022-02-07
EP3518911B1 (en) 2021-08-25
WO2018064231A1 (en) 2018-04-05
SG11201901759XA (en) 2019-04-29
BR112019004276A2 (pt) 2019-06-04
CN109715149A (zh) 2019-05-03
RS62660B1 (sr) 2021-12-31
KR20190058568A (ko) 2019-05-29
US20230129787A1 (en) 2023-04-27
LT3518911T (lt) 2021-12-10
IL265537B2 (en) 2023-04-01
ES2898072T3 (es) 2022-03-03
JP2019532934A (ja) 2019-11-14
HUE057064T2 (hu) 2022-04-28
IL265537A (en) 2019-05-30
KR20230152814A (ko) 2023-11-03
SG10202104282SA (en) 2021-06-29
EP3518911A1 (en) 2019-08-07

Similar Documents

Publication Publication Date Title
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
HK1258098A1 (zh) 治療癌症的方法
IL263925A (en) Methods of treating ovarian cancer
CL2018003123A1 (es) Terapia de combinación para el tratamiento del cáncer
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
BR112018003269A2 (pt) conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização
TW201611847A (en) Compounds and compositions for treating EGFR expressing tumors
NZ731467A (en) Anti-tim3 antibodies and methods of use
EA201990296A1 (ru) Антитела против siglec-7 для лечения рака
EA201892802A1 (ru) Производные аденозина для применения при лечении рака
KR20180084772A (ko) 암 치료를 위한 조합 치료법
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
IL262342A (en) Cancer treatment methods
BR112017004444A2 (pt) novos anticorpos anti-mfi2 e métodos de uso
MX2017006015A (es) Composiciones para usar en el tratamiento de cancer renal.
MX2016009663A (es) Derivados de icariina.
MX2017006026A (es) Apilimod para uso en el tratamiento de cancer colorrectal.
KR102377742B1 (ko) 암치료약
DK3253208T3 (da) Kombinationsterapier til anvendelse i behandlingen af brystcancer
PH12016501838A1 (en) Compounds and their methods of use
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين
BR112018012884A2 (pt) novos anticorpos anti-mmp16 e métodos de uso
DK3576740T3 (da) Cancerbehandling
CY1125266T1 (el) To rad1901 για χρηση στη θεραπεια του καρκινου των ωοθηκων